Find below answers to frequently asked questions for applicants to
Global Noncommunicable Diseases and Injury Across the Lifespan: Exploratory Research (R21 Clinical Trials Optional) (PAR-19-059).
Learn more about the
Global Noncommunicable Diseases and Injury Research.
Please check this page for updates.
Updated November 7, 2018
Is a collaboration with a U.S. partner required?
The low- and middle-income country applicants are not required to submit their application in collaboration with a U.S. partner.
The applicant institution must be from the low-, lower-middle or upper-middle income country.
Are collaborations with U.S. or other High-Income country partners allowed?
Personnel from the U.S. and other high-income countries are eligible to be engaged on applications to this FOA. U.S. investigators may serve as Co-PIs. Non-U.S. high-income country (HIC) investigators are not eligible as multiple PD/PIs; they may serve as consultants.
May I submit if my topic is eligible for the FOA but does not fit any of the participating NIH institutes other than Fogarty?
If your R21 application is an eligible topic for the FOA, you do not have to find a NIH specific Institute or Center (IC) "home" for the application before you submit. An assignment will be given during application submission. Prior discussion with other interested ICs is helpful for referral purposes and for subject matter expertise, but it is not required.
Do foreign sites require DUNS number?
Yes, they do. As the application is required to come from a foreign site, applications without a DUNS number will not be awarded.
What should be the distribution of funds to the low-, lower-middle or upper-middle income sites?
At least 51 percent of the total direct costs should be allocated to the low-, lower-middle and upper-middle income country sites. If there are multiple low-, lower-middle and upper-middle income sites, the combined expenditure of the sites should be at least 51 percent.
What is the page limit for the "Research Strategy" section?
Six pages maximum.